NO20054775L - Biaryl-substituerte triazoler som natriumkanalblokkere - Google Patents

Biaryl-substituerte triazoler som natriumkanalblokkere

Info

Publication number
NO20054775L
NO20054775L NO20054775A NO20054775A NO20054775L NO 20054775 L NO20054775 L NO 20054775L NO 20054775 A NO20054775 A NO 20054775A NO 20054775 A NO20054775 A NO 20054775A NO 20054775 L NO20054775 L NO 20054775L
Authority
NO
Norway
Prior art keywords
compounds
pain
alone
pharmaceutically acceptable
effective amount
Prior art date
Application number
NO20054775A
Other languages
English (en)
Norwegian (no)
Other versions
NO20054775D0 (no
Inventor
Prasun K Chakravarty
Williams H Parsons
Michael H Fisher
Brenda Palucki
Min K Park
Bishan Zhou
James P Carey
Douglas E Frantz
Michael H Kress
Damian Weaver
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of NO20054775D0 publication Critical patent/NO20054775D0/no
Publication of NO20054775L publication Critical patent/NO20054775L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00Anaesthetics
    • A61P23/02Local anaesthetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/101,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20054775A 2003-03-18 2005-10-17 Biaryl-substituerte triazoler som natriumkanalblokkere NO20054775L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45595203P 2003-03-18 2003-03-18
PCT/US2004/007830 WO2004083190A1 (en) 2003-03-18 2004-03-12 Biaryl substituted triazoles as sodium channel blockers

Publications (2)

Publication Number Publication Date
NO20054775D0 NO20054775D0 (no) 2005-10-17
NO20054775L true NO20054775L (no) 2005-12-16

Family

ID=33030073

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20054775A NO20054775L (no) 2003-03-18 2005-10-17 Biaryl-substituerte triazoler som natriumkanalblokkere

Country Status (34)

Country Link
US (2) US7326726B2 (is)
EP (1) EP1606269B1 (is)
JP (1) JP4482554B2 (is)
KR (1) KR100737721B1 (is)
CN (2) CN1788002A (is)
AR (1) AR044503A1 (is)
AT (1) ATE412639T1 (is)
AU (1) AU2004221885C1 (is)
BR (1) BRPI0408407A (is)
CA (1) CA2519252C (is)
CL (1) CL2004000551A1 (is)
CY (1) CY1108720T1 (is)
DE (1) DE602004017438D1 (is)
DK (1) DK1606269T3 (is)
EC (1) ECSP056018A (is)
EG (1) EG25994A (is)
ES (1) ES2314387T3 (is)
HR (1) HRP20050816A2 (is)
IS (1) IS8001A (is)
JO (1) JO2480B1 (is)
MA (1) MA27665A1 (is)
MX (1) MXPA05009847A (is)
MY (1) MY142651A (is)
NO (1) NO20054775L (is)
NZ (1) NZ542205A (is)
PE (1) PE20041066A1 (is)
PL (1) PL1606269T3 (is)
PT (1) PT1606269E (is)
RU (1) RU2356897C2 (is)
SI (1) SI1606269T1 (is)
TW (1) TWI337605B (is)
UA (1) UA81660C2 (is)
WO (2) WO2004083189A1 (is)
ZA (1) ZA200506906B (is)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2510455C (en) 2002-12-19 2013-03-12 The Scripps Research Institute Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding
MY142651A (en) * 2003-03-18 2010-12-15 Merck Sharp & Dohme Biaryl substituted triazoles as sodium channel blockers
US20090074890A1 (en) * 2003-11-10 2009-03-19 Park Min K Substituted Triazoles as Sodium Channel Blockers
WO2005118511A2 (en) 2004-05-20 2005-12-15 The Scripps Research Institute Compounds, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding
TW200728258A (en) 2005-10-10 2007-08-01 Glaxo Group Ltd Novel compounds
TW200730494A (en) 2005-10-10 2007-08-16 Glaxo Group Ltd Novel compounds
JP5139307B2 (ja) 2005-10-10 2013-02-06 グラクソ グループ リミテッド ナトリウムチャネルモジュレーターとしてのプロリンアミド誘導体
EP2117538A1 (en) * 2007-01-24 2009-11-18 Glaxo Group Limited Pharmaceutical compositions comprising 2-methoxy-5- (5-trifluoromethyl-tetrazol-i-yl-benzyl) - (2s-phenyl-piperidin-3s-yl-)
CN101679319B (zh) 2007-02-08 2014-07-09 辛塔医药品有限公司 用于治疗增生性病症如癌症的三唑类化合物
ES2601856T3 (es) 2007-06-08 2017-02-16 Mannkind Corporation Inhibidores de la IRE-1A
DK2464645T3 (en) 2009-07-27 2017-10-23 Gilead Sciences Inc CONDENSED, HETEROCYCLIC COMPOUNDS AS IRON CHANNEL MODULATORS
MX2012015096A (es) 2010-07-02 2013-05-28 Gilead Sciences Inc Compuestos heterociclicos fusionados como moduladores del canal ion.
AU2012253653A1 (en) 2011-05-10 2013-05-02 Gilead Sciences, Inc. Fused heterocyclic compounds as sodium channel modulators
UY34171A (es) 2011-07-01 2013-01-31 Gilead Sciences Inc Compuestos heterocíclicos fusionados como moduladores del canal iónico
NO3175985T3 (is) 2011-07-01 2018-04-28
EP2755961A1 (en) 2011-09-16 2014-07-23 Pfizer Inc Solid forms of a transthyretin dissociation inhibitor
WO2013131018A1 (en) * 2012-03-02 2013-09-06 Zalicus Pharmaceuticals Ltd. Biaryl inhibitors of the sodium channel
TWI568722B (zh) 2012-06-15 2017-02-01 葛蘭馬克製藥公司 作爲mPGES-1抑制劑之三唑酮化合物
EP2967073B9 (en) 2013-03-15 2019-04-10 Bristol-Myers Squibb Company Lxr modulators
EP3237379B1 (en) 2014-12-23 2022-04-06 Convergence Pharmaceuticals Limited Process for preparing alpha-carboxamide pyrrolidine derivatives
JP6616244B2 (ja) * 2015-05-29 2019-12-04 北興化学工業株式会社 新規なヒドロキシフェニルボロン酸エステルとその製造方法、およびヒドロキシビフェニル化合物の製造法
WO2019071162A2 (en) 2017-10-05 2019-04-11 Biogen Inc. PROCESS FOR THE PREPARATION OF PYRROLIDINE ALPHA-CARBOXAMIDE DERIVATIVES
KR102512548B1 (ko) 2017-12-22 2023-03-22 삼성디스플레이 주식회사 유기 전계 발광 소자 및 유기 전계 발광 소자용 함질소 화합물
EP3762367A1 (en) * 2018-03-09 2021-01-13 PI Industries Ltd. Heterocyclic compounds as fungicides
CN108863965A (zh) * 2018-06-25 2018-11-23 青岛科技大学 一锅法制备1,2,4-三氮唑-3-甲酰胺的方法
CN108794413A (zh) * 2018-06-25 2018-11-13 青岛科技大学 一种1,2,4-三氮唑-3-甲酰胺的合成方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US875782A (en) * 1907-04-29 1908-01-07 Walter H Cook Fast-nut.
TW226993B (is) * 1992-05-29 1994-07-21 Kumiai Chemical Industry Co
US5455252A (en) * 1993-03-31 1995-10-03 Syntex (U.S.A.) Inc. Optionally substituted 6,8-quinolines
IT1292091B1 (it) * 1997-06-05 1999-01-25 Geange Ltd Derivati eterociclici aromatici azotati,procedimento per la loro preparazione e loro impiego come antigestativi,immunosoppressori e
GB9726987D0 (en) 1997-12-22 1998-02-18 Glaxo Group Ltd Compounds
AU782353B2 (en) * 1999-03-26 2005-07-21 Euro-Celtique S.A. Aryl substituted pyrazoles, imidazoles, oxazoles, thiazoles and pyrroles, and the use thereof
AR029489A1 (es) 2000-03-10 2003-07-02 Euro Celtique Sa Piridinas, pirimidinas, pirazinas, triazinas sustituidas por arilo, composiciones farmaceuticas y el uso de las mismas para la manufactura de un medicamento
US6962936B2 (en) * 2001-04-27 2005-11-08 Vertex Pharmaceuticals Incorporated Triazole-derived kinase inhibitors and uses thereof
US6797722B2 (en) * 2002-05-03 2004-09-28 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Use of 3-(2-ethylphenyl)-5-(3-methoxyphenyl)-1H-1,2,4-triazole for the treatment of autoimmune diseases
CN1665500A (zh) * 2002-07-09 2005-09-07 百时美施贵宝公司 用作抗糖尿病和抗肥胖症试剂的取代杂环衍生物及方法
KR100467668B1 (ko) * 2002-08-07 2005-01-24 씨제이 주식회사 1,2,4-트리아졸 유도체, 그 제조방법 및 약제학적 조성물
KR100470075B1 (ko) * 2002-11-21 2005-02-05 씨제이 주식회사 1,2,4-트리아졸 유도체, 그 제조방법 및 약제학적 조성물
JO2397B1 (en) * 2002-12-20 2007-06-17 ميرك شارب اند دوم كوربوريشن Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors
MY142651A (en) * 2003-03-18 2010-12-15 Merck Sharp & Dohme Biaryl substituted triazoles as sodium channel blockers
US20090074890A1 (en) * 2003-11-10 2009-03-19 Park Min K Substituted Triazoles as Sodium Channel Blockers

Also Published As

Publication number Publication date
US7572822B2 (en) 2009-08-11
MA27665A1 (fr) 2005-12-01
ZA200506906B (en) 2007-02-28
UA81660C2 (ru) 2008-01-25
ECSP056018A (es) 2006-01-27
HRP20050816A2 (hr) 2006-04-30
US20080171777A1 (en) 2008-07-17
BRPI0408407A (pt) 2006-03-21
JO2480B1 (en) 2009-01-20
CL2004000551A1 (es) 2005-01-21
CY1108720T1 (el) 2013-09-04
CA2519252C (en) 2008-11-18
TWI337605B (en) 2011-02-21
MY142651A (en) 2010-12-15
AU2004221885A1 (en) 2004-09-30
TW200505876A (en) 2005-02-16
DE602004017438D1 (de) 2008-12-11
JP2006520782A (ja) 2006-09-14
PE20041066A1 (es) 2005-01-22
US20050119261A1 (en) 2005-06-02
ATE412639T1 (de) 2008-11-15
SI1606269T1 (sl) 2009-02-28
JP4482554B2 (ja) 2010-06-16
NO20054775D0 (no) 2005-10-17
NZ542205A (en) 2008-11-28
US7326726B2 (en) 2008-02-05
PT1606269E (pt) 2008-12-16
AU2004221885B2 (en) 2010-04-22
CN1788002A (zh) 2006-06-14
KR100737721B1 (ko) 2007-07-11
EP1606269A1 (en) 2005-12-21
RU2356897C2 (ru) 2009-05-27
RU2005132168A (ru) 2006-04-27
PL1606269T3 (pl) 2009-04-30
AU2004221885C1 (en) 2010-09-23
IS8001A (is) 2005-08-29
WO2004083189A1 (en) 2004-09-30
ES2314387T3 (es) 2009-03-16
CN101289428A (zh) 2008-10-22
DK1606269T3 (da) 2009-02-09
CA2519252A1 (en) 2004-09-30
MXPA05009847A (es) 2005-12-05
EP1606269B1 (en) 2008-10-29
KR20050109583A (ko) 2005-11-21
EG25994A (en) 2012-11-28
AR044503A1 (es) 2005-09-14
WO2004083190A1 (en) 2004-09-30

Similar Documents

Publication Publication Date Title
NO20054775L (no) Biaryl-substituerte triazoler som natriumkanalblokkere
NO20062676L (no) Substituerte triazoler som natriumkanalblokkere
NO20091620L (no) Boronsyre og estere som inhibitorer av fettsyreamidhydrolaser
WO2007112345A3 (en) Use of cyclosporin alkene analogues for preventing or treating viral-induced disorders
WO2007145922A3 (en) Benzazepinones as sodium channel blockers
WO2011027249A3 (en) Benzimidazole derivatives
WO2007075524A3 (en) Substituted piperidines as calcium channel blockers
WO2007112357A3 (en) Use of cyclosporin alkyne analogues for preventing or treating viral-induced disorders
WO2009066041A3 (fr) Derives de 1,2,4,5-tetrahydro-3h-benzazepines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2010095768A8 (en) 4 -isopropylphenyl glucitol compounds as sglt1 inhibitors
ZA200700758B (en) Polysulfated glycosides and salts thereof
TNSN05246A1 (en) Use of 10-hydroxy-10, 11-dihydrocarbamazepine derivatives for the treatment of affective disorders
EA201001094A1 (ru) Производные индазола
NO20002099L (no) 6,11-bro-erytromycinderivater
NO20001169L (no) 6,9-bro erythromycinderivater
MX2022009967A (es) Compuestos para el tratamiento de la infeccion por coronavirus.
BR0311136A (pt) composto ou um sal, enanciÈmero, diaestereÈmero ou éster hidrolisável in vivo ou mistura dos mesmos farmaceuticamente aceitável, composição, e, método para inibir a atividade de fator letal (lf) liberado de bactérias em um mamìfero
WO2001014358A3 (en) Substituted (aminoiminomethyl or aminomethyl) dihydrobenzofurans and benozopyrans
WO2010045582A3 (en) Compositions and methods for treating or preventing hypoxic or ischemic injury
JP2008531613A5 (is)
WO2005037213A3 (en) Antiinflammatory inhibitors of respiratory burst in adherent neutrophils
WO2007084394A3 (en) 2,5 diaza-bicyclo[2.2.1]heptane derivatives as calcium channel blockers
WO2023217800A3 (en) Synthesis of glycosylated hydroxytryptamine compounds and methods of their use
WO2023250141A3 (en) Methods of treating neurological ventilatory insufficiency
MX2023004435A (es) Compuestos y composiciones para el tratamiento de la criptosporidiosis.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application